Outlook Therapeutics is trading at $0.54, down 5.37%, with no independently verified fresh catalyst identified.

  • The supplied alert reports a Nasdaq minimum-bid-price notice on September 30, but available search results did not independently confirm it.
  • Shares fell 8.34% on September 30. The reported listing-compliance concern could weigh on sentiment, but its connection to the current decline is unconfirmed.
  • Broader index moves are mixed and modest, offering no clear explanation for the stock-specific drop.